Sartorius supports development of coronavirus vaccine
Sartorius supports the development of the first vaccine candidate against the novel coronavirus to enter clinical trials
25 Mar 2020
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. CanSinoBIO and the Institute of Bioengineering used Sartorius’ BIOSTAT® STR single-use bioreactor system for the upstream preparation of the recombinant vaccine, thus ensuring the rapid linear amplification of the adenovirus vector (Ad5-nCoV) and ultimately saving time during development.
The BIOSTAT® STR single-use bioreactor system comes with updated BioPAT® toolbox for process monitoring, as well as Flexsafe® STR integrated, single-use bioprocess bags. It has been proven to be used for vaccine manufacturing because it offers rapid scalability and flexibility to adapt to fluctuating demand. The single use bags prevent cross-contamination, and reduce the time needed for washing and sanitation typical in stainless steel bioreactors. As such, the amount of time needed to prepare a vector for a vaccine is shortened from several months to (several) weeks.
“We are pleased that we can help our clients and partners accelerate vaccine development while maintaining compliance with safety protocols, thereby allowing us to contribute to better health for more people,” said Huang Xian, Head of Marketing at Sartorius BPS China. “The Sartorius team is making every effort to quickly allocate the staff and equipment needed to support the early stages of vaccine development during this high-risk period. We hope that Ad5-nCoV will achieve approval as early as possible, so it can help stop the spread of the novel coronavirus worldwide.”
This is the second collaboration from Sartorius, CanSinoBIO, and the Institute of Bioengineering to accelerate vaccine development. In October 2017, Sartorius’ BIOSTAT® STR50 bioreactor system was used during CanSinoBIO’s and the Institute of Bioengineering’s joint development of a recombinant vaccine against Ebola virus disease. This was the first registered Ebola vaccine in the world.
For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>
Related Products
Request Quote for All Products
BIOSTAT® CultiBag STR Plus
Sartorius GroupInnovative Bioreactor, Sensor and Stirrer Technology The BIOSTAT® CultiBag STR Plus is a stirred single use bioreactor available from small scale to large scale cultivation up to 1000L. Its design is entirely based on the conventional gold standards coming from the stainless steel systems, allowing for easy scale-up and transfer from stainless steel solutions. The BIOSTAT® CultiBag STR Plus consists of one BIOSTAT® STR Plus Control Tower, one bag holder, a single-use CultiBag STR and superior BioPAT® MFCS/DA data logging software. Single as well as twin versions are available.It is ideal for: Cell Culture applications Industrial and academic research Process development Process optimization Pilot scale production Seed cultivation for large scale bioreactors Production scale Features: Completely single use bioreactor in traditional design Top driven stirrer with magnetic coupling Application driven fully flexible gassing system Available as single and twin version User-friendly touch screen interface for easy operation Single use optical DO & pH sensors for measurement Single use bags available with working volumes of 50L, 200L, 500L and 1000L Validation & Extractible guide available